000			02351 a2200637 4500
005			20250516024259.0
264		0	_c20111212
008			201112s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdq738 _2doi
040			_aNLM _beng _cNLM
100	1		_aViale, G
245	0	0	_aWhich patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cOct 2011
300			_a2201-7 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aAromatase Inhibitors _xadministration & dosage
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Administration Schedule
650	0	4	_aErbB Receptors _xbiosynthesis
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aKi-67 Antigen _xbiosynthesis
650	0	4	_aLetrozole
650	0	4	_aMiddle Aged
650	0	4	_aNitriles _xadministration & dosage
650	0	4	_aPrognosis
650	0	4	_aReceptors, Estrogen _xbiosynthesis
650	0	4	_aReceptors, Progesterone _xbiosynthesis
650	0	4	_aTamoxifen _xadministration & dosage
650	0	4	_aTriazoles _xadministration & dosage
700	1		_aRegan, M M
700	1		_aDell'Orto, P
700	1		_aMastropasqua, M G
700	1		_aMaiorano, E
700	1		_aRasmussen, B B
700	1		_aMacGrogan, G
700	1		_aForbes, J F
700	1		_aParidaens, R J
700	1		_aColleoni, M
700	1		_aLáng, I
700	1		_aThürlimann, B
700	1		_aMouridsen, H
700	1		_aMauriac, L
700	1		_aGelber, R D
700	1		_aPrice, K N
700	1		_aGoldhirsch, A
700	1		_aGusterson, B A
700	1		_aCoates, A S
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 22 _gno. 10 _gp. 2201-7
856	4	0	_uhttps://doi.org/10.1093/annonc/mdq738 _zAvailable from publisher's website
999			_c20611944 _d20611944